Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2023 August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights ● EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ● Genmab and AbbVie Inc. (AbbVie) announced positive topline results from the Phase 1/2 EPCORE™ NHL-1 trial evaluating e ...